G1 THERAPEUTICS INC. - COMMON STOCK

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Sep 2023 16:15:21 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational Highlights

02 Aug 2023 06:30:27 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in Two August Investor Conferences

31 Jul 2023 14:30:27 By Nasdaq GlobeNewswire

New Publication Highlights Real World Impact of Trilaciclib on Myelosuppressive Events in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)

31 Jul 2023 08:30:40 By Nasdaq GlobeNewswire

G1 Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 2, 2023

26 Jul 2023 09:00:31 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jul 2023 16:15:03 By Nasdaq GlobeNewswire

Trilaciclib Increases Pool of Memory T Cells in the Tumor Microenvironment Responsible for Long Term Immune Surveillance and Efficacy

04 Jun 2023 07:13:44 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jun 2023 16:40:59 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Appointment of Monica Thomas as General Counsel

22 May 2023 16:45:22 By Nasdaq GlobeNewswire

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

16 May 2023 07:30:11 By Nasdaq GlobeNewswire

New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate (ADC)

10 May 2023 07:31:04 By Nasdaq GlobeNewswire

G1 Therapeutics Provides First Quarter 2023 Financial Results and Operational Highlights

03 May 2023 06:30:55 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 May 2023 17:00:50 By Nasdaq GlobeNewswire

G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

26 Apr 2023 12:45:27 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare Conference

11 Apr 2023 12:30:49 By Nasdaq GlobeNewswire

G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights

01 Mar 2023 06:30:27 By Nasdaq GlobeNewswire

G1 Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

28 Feb 2023 14:10:49 By Nasdaq GlobeNewswire

G1 Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 1, 2023

22 Feb 2023 10:00:17 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)

13 Feb 2023 06:00:38 By Nasdaq GlobeNewswire

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Feb 2023 16:46:01 By Nasdaq GlobeNewswire